1. Name of trial drug: Deferasirox
  2. For what level of MDS severity risk: Low, or low to moderate
  3. What subtype of MDS: All
  4. Aims and benefits: This trial will investigate how exactly chelation therapy can affect the health of patients with MDS and iron overload
  5. Main basic inclusion criteria: MDS patients with Transfusional Iron Overload. Age over 18
  6. Main basic exclusion criteria:
  7. Trial sites/locations and name of physician in charge of trial:
  8. More information: https://clinicaltrials.gov/ct2/show/NCT00940602

Please read information and always discuss trial information with your own physician.
Download information

Learn more about clinical trials

Check other current clinical trials

Free donations by shopping